The co-founder of bankrupt genetic analysis company 23andMe won an auction for the firm’s assets, agreeing, along with a ...

But what about the other end of the spectrum? Let's take a quick look at the two worst performers on the Nasdaq-100 in May 2025.

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

TB Alternative Assets Ltd. has joined the biotech investing party by purchasing 3,158 shares of Regeneron Pharmaceuticals ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has ...

A significant trading signal occurred for Regeneron Pharma stock at a price of $501.83, after which REGN rose up to 3.2%.

Regeneron Pharmaceuticals logged a 4.0% change during today's afternoon session, and is now trading at a price of $513.17 per ...

Intellectus Partners LLC recently doubled down on Regeneron Pharmaceuticals, upping its stake by 92.7% in Q1. The firm now ...

Bankrupt genetic analysis company 23andMe will hold a second auction for its cache of DNA data with an opening bid of $305 ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...